Literature DB >> 19525468

Quantification of translocator protein (18 kDa) in the human brain with PET and a novel radioligand, (18)F-PBR06.

Yota Fujimura1, Sami S Zoghbi, Fabrice G Simèon, Andrew Taku, Victor W Pike, Robert B Innis, Masahiro Fujita.   

Abstract

UNLABELLED: Translocator protein (TSPO) (18 kDa), formerly called the peripheral benzodiazepine receptor, is upregulated on activated microglia and macrophages and is, thus, a biomarker of inflammation. We previously reported that an (11)C-labeled aryloxyanilide (half-life, 20 min) was able to quantify TSPOs in the healthy human brain. Because many PET centers would benefit from a longer-lived (18)F-labeled radioligand (half-life, 110 min), the objective of this study was to evaluate the ability of a closely related aryloxyanilide ((18)F-N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline [(18)F-PBR06]) to quantify TSPOs in the healthy human brain.
METHODS: A total of 9 human subjects were injected with (18)F-PBR06 (approximately 185 MBq) and scanned for 5 h, with rest periods outside the camera. The concentrations of (18)F-PBR06, separated from radiometabolites, were measured in arterial plasma.
RESULTS: Modeling of regional brain and plasma data showed that a 2-tissue-compartment model was superior to a 1-tissue-compartment model. Even if data for all time points were used for the fitting, concentrations of brain activity measured with PET were consistently greater than the modeled values at late (280-300 min) but not at early time points. The greater values may have been caused by the slow accumulation of radiometabolites in the brain. To determine an adequate time for more accurate measurement of distribution volume (V(T)), which is the summation of receptor binding and nondisplaceable activity, we investigated which scan duration would be associated with maximal or near-maximal identifiability. We found that a scan of 120 min provided the best identifiability of V(T) (approximately 2%). The images showed no significant defluorination.
CONCLUSION: (18)F-PBR06 can quantify TSPOs in the healthy human brain using 120 min of image acquisition and concurrent measurements of radioligand in plasma. Although brain activity is likely contaminated with radiometabolites, the percentage contamination is thought to be small (<10%), because values of distribution volume are stable during 60-120 min and vary by less than 10%. (18)F-PBR06 is a longer-lived and promising alternative to (11)C-labeled radioligands to measure TSPOs as a biomarker of inflammation in the brain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19525468      PMCID: PMC2786064          DOI: 10.2967/jnumed.108.060186

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  26 in total

1.  Cerebral blood flow, blood volume and oxygen utilization. Normal values and effect of age.

Authors:  K L Leenders; D Perani; A A Lammertsma; J D Heather; P Buckingham; M J Healy; J M Gibbs; R J Wise; J Hatazawa; S Herold
Journal:  Brain       Date:  1990-02       Impact factor: 13.501

2.  Labelling of peripheral-type benzodiazepine binding sites in human brain with [3H]PK 11195: anatomical and subcellular distribution.

Authors:  A Doble; C Malgouris; M Daniel; N Daniel; F Imbault; A Basbaum; A Uzan; C Guérémy; G Le Fur
Journal:  Brain Res Bull       Date:  1987-01       Impact factor: 4.077

3.  Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography.

Authors:  R E Carson; M A Channing; R G Blasberg; B B Dunn; R M Cohen; K C Rice; P Herscovitch
Journal:  J Cereb Blood Flow Metab       Date:  1993-01       Impact factor: 6.200

4.  Evidence for species differences in 'peripheral' benzodiazepine receptors: an autoradiographic study.

Authors:  U Cymerman; A Pazos; J M Palacios
Journal:  Neurosci Lett       Date:  1986-05-15       Impact factor: 3.046

Review 5.  Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents.

Authors:  Rikki N Waterhouse
Journal:  Mol Imaging Biol       Date:  2003 Nov-Dec       Impact factor: 3.488

6.  PET study of carbon-11-PK 11195 binding to peripheral type benzodiazepine sites in glioblastoma: a case report.

Authors:  S Pappata; P Cornu; Y Samson; C Prenant; J Benavides; B Scatton; C Crouzel; J J Hauw; A Syrota
Journal:  J Nucl Med       Date:  1991-08       Impact factor: 10.057

7.  Interaction of benzodiazepines with mouse macrophages.

Authors:  F Zavala; J Haumont; M Lenfant
Journal:  Eur J Pharmacol       Date:  1984-11-27       Impact factor: 4.432

8.  Effects of temporal sampling, glucose metabolic rates, and disruptions of the blood-brain barrier on the FDG model with and without a vascular compartment: studies in human brain tumors with PET.

Authors:  R A Hawkins; M E Phelps; S C Huang
Journal:  J Cereb Blood Flow Metab       Date:  1986-04       Impact factor: 6.200

9.  Single-step high-yield radiosynthesis and evaluation of a sensitive 18F-labeled ligand for imaging brain peripheral benzodiazepine receptors with PET.

Authors:  Emmanuelle Briard; Sami S Zoghbi; Fabrice G Siméon; Masao Imaizumi; Jonathan P Gourley; H Umesha Shetty; Shuiyu Lu; Masahiro Fujita; Robert B Innis; Victor W Pike
Journal:  J Med Chem       Date:  2009-02-12       Impact factor: 7.446

10.  'Peripheral' benzodiazepine binding sites in human brain and kidney: autoradiographic studies.

Authors:  A Pazos; U Cymerman; A Probst; J M Palacios
Journal:  Neurosci Lett       Date:  1986-05-15       Impact factor: 3.046

View more
  33 in total

1.  PET imaging of stroke-induced neuroinflammation in mice using [18F]PBR06.

Authors:  Frederick M Lartey; G-One Ahn; Bin Shen; Keith-Travis Cord; Tenille Smith; Joshua Y Chua; Sahar Rosenblum; Hongguang Liu; Michelle L James; Sophia Chernikova; Star W Lee; Laura J Pisani; Rabindra Tirouvanziam; John W Chen; Theo D Palmer; Frederick T Chin; Raphael Guzman; Edward E Graves; Billy W Loo
Journal:  Mol Imaging Biol       Date:  2013-07-09       Impact factor: 3.488

2.  Biodistribution and Radiation Dosimetry of 124I-DPA-713, a PET Radiotracer for Macrophage-Associated Inflammation.

Authors:  Catherine A Foss; Donika Plyku; Alvaro A Ordonez; Julian Sanchez-Bautista; Hailey B Rosenthal; Il Minn; Martin A Lodge; Martin G Pomper; George Sgouros; Sanjay K Jain
Journal:  J Nucl Med       Date:  2018-04-26       Impact factor: 10.057

3.  Quantitation of translocator protein binding in human brain with the novel radioligand [18F]-FEPPA and positron emission tomography.

Authors:  Pablo M Rusjan; Alan A Wilson; Peter M Bloomfield; Irina Vitcu; Jeffrey H Meyer; Sylvain Houle; Romina Mizrahi
Journal:  J Cereb Blood Flow Metab       Date:  2011-04-27       Impact factor: 6.200

4.  Validation of an automatic reference region extraction for the quantification of [18F]DPA-714 in dynamic brain PET studies.

Authors:  Daniel García-Lorenzo; Sonia Lavisse; Claire Leroy; Catriona Wimberley; Benedetta Bodini; Philippe Remy; Mattia Veronese; Federico Turkheimer; Bruno Stankoff; Michel Bottlaender
Journal:  J Cereb Blood Flow Metab       Date:  2017-02-09       Impact factor: 6.200

5.  Translocator protein (18 kDa) polymorphism (rs6971) explains in-vivo brain binding affinity of the PET radioligand [(18)F]-FEPPA.

Authors:  Romina Mizrahi; Pablo M Rusjan; James Kennedy; Bruce Pollock; Benoit Mulsant; Ivonne Suridjan; Vincenzo De Luca; Alan A Wilson; Sylvain Houle
Journal:  J Cereb Blood Flow Metab       Date:  2012-04-04       Impact factor: 6.200

Review 6.  New and Old TSPO PET Radioligands for Imaging Brain Microglial Activation in Neurodegenerative Disease.

Authors:  Laura Best; Christine Ghadery; Nicola Pavese; Yen Foung Tai; Antonio P Strafella
Journal:  Curr Neurol Neurosci Rep       Date:  2019-04-02       Impact factor: 5.081

Review 7.  Development of (18)F-labeled radiotracers for neuroreceptor imaging with positron emission tomography.

Authors:  Peter Brust; Jörg van den Hoff; Jörg Steinbach
Journal:  Neurosci Bull       Date:  2014-08-29       Impact factor: 5.203

Review 8.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

9.  Biodistribution and radiation dosimetry in humans of a new PET ligand, (18)F-PBR06, to image translocator protein (18 kDa).

Authors:  Yota Fujimura; Yasuyuki Kimura; Fabrice G Siméon; Leah P Dickstein; Victor W Pike; Robert B Innis; Masahiro Fujita
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

10.  A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation.

Authors:  William C Kreisl; Kimberly J Jenko; Christina S Hines; Chul Hyoung Lyoo; Winston Corona; Cheryl L Morse; Sami S Zoghbi; Thomas Hyde; Joel E Kleinman; Victor W Pike; Francis J McMahon; Robert B Innis
Journal:  J Cereb Blood Flow Metab       Date:  2012-09-12       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.